… (PETs) share numerous features with gastrointestinal neuroendocrine (carcinoid) tumors.
Targets of novel therapeutic strategies previously assessed in carcinoid tumors were analyzed …

… Progress in both areas should advance preclinical assays of novel therapeutics. In that
regard, more progress in establishing patient-derived spheroid, organoid, and xenograft models …

… A similar use of molecular markers is in patients with well … tumor that would be responsive
to platinum-based therapies. … differentiated tumors (panNECs) will guide a change of therapy …

… , overexpress this marker (65) and gastrinomas of the pancreas show low expression …
pancreatic marker. Nuclear positivity for PR has been reported in most pancreatic endocrine tumors…

… The overexpression of the src-like kinase LCK (p56 LCK ) is particularly relevant, and offers
a potential novel therapeutic target for PETs. LCK is an src-like non-receptor protein tyrosine …

… be used to study liver metastasis and to test novel therapeutic strategies (74,75). The limitations
… Lastly, improving detection of aggressive tumors by evaluating novel molecular markers …

… Over the years, technological progress and knowledge increase have driven an evolving
pathological classification of pituitary endocrine tumours, from a tinctorial classification to an …

… molecular markers for endocrine progression that could be useful as prognostic markers or
therapeutic … may facilitate the development of novel therapies and molecular screening tests. …

… In conclusion, while there exists optimism, as novel therapeutic strategies are emerging for
patients with GEP ETs, the increasing number of options also requires an increased need for …

… Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic
neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted …